Anne Luetkemeyer
Infectious Disease · San Francisco, CANPI 1346378940
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,182 of the $5,228 with a category attached, or 60.9%. Shionogi Inc accounts for 63.0% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $3,459, 4.4 times the $785 reported in 2020.
Across 21 payments — averaging $248.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$3K
- Merck$2K
- Gilead$176
- Viiv Healthcare Company$114
Across 83 payments — averaging $7630.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$299K
- GSK$139K
- Merck$94K
- Mayne Pharma Commercial LLC$56K
- Gilead$25K
- Novartis$13K
- plus $7K from 2 others
What the payments were for
- Speaking & faculty fees$3,18261%
- Travel & lodging$1,27824%
- Food & beverage$76815%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 2 | $3,293 |
| Merck | 16 | $1,645 |
| Gilead | 2 | $176 |
| Viiv Healthcare Company | 1 | $114 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,228 in reported general payments places this provider in the 80th percentile of 856 infectious disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 55 | $214,947 |
| TivicayDolutegravir Sodium | 42 | $93,660 |
| DovatoDolutegravir Sodium/Lamivudine | 27 | $77,979 |
| PifeltroDoravirine | 44 | $74,767 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 13 | $52,309 |
| JulucaDolutegravir/Rilpivirine | 12 | $37,502 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $37,385 |
| Abilify MaintenaAripiprazole | 13 | $35,125 |
| PrezcobixDarunavir/Cobicistat | 13 | $28,971 |
| Invega SustennaPaliperidone Palmitate | 12 | $27,119 |
| OzempicSemaglutide | 11 | $8,326 |
| JardianceEmpagliflozin | 13 | $6,491 |
| Praluent PenAlirocumab | 12 | $5,769 |
| Lidocaine | 28 | $3,058 |
| Varenicline Tartrate | 11 | $2,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTivicay, Dovato, Juluca, Triumeq | $114 | $246,52692 claims |
| GileadBiktarvy | $176 | $214,94755 claims |
| MerckPifeltro | $1,645 | $74,76744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 856 infectious disease providers in California.
Other infectious disease in San Francisco
- Shawn HasslerSan Francisco$433K
- Abhijit LimayeSan Francisco$152K
- Joel PalefskySan Francisco$68K
- Monica GandhiSan Francisco$60K
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- James McKinnellTorrance$762K
- Jay GladsteinLos Angeles$657K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.